Indian Market Plunges 2%, But Select Stocks Show Strength with Buy Ratings

STOCK-INVESTMENT-IDEAS
Whalesbook Logo
AuthorIshaan Verma|Published at:
Indian Market Plunges 2%, But Select Stocks Show Strength with Buy Ratings
Overview

Indian equity benchmarks plunged over 2% on March 27, fueled by escalating Middle East tensions and oil price surges, pushing the rupee to record lows. Amidst this broad-based sell-off, select stocks like Granules India, Federal Bank, Emcure Pharmaceuticals, Larsen & Toubro, Mankind Pharma, Delhivery, and Aditya Infotech demonstrated technical resilience. Analysts maintain a predominantly 'Buy' consensus for these names, setting ambitious price targets that contrast sharply with the prevailing market fear. This divergence suggests pockets of opportunity are emerging for discerning investors, even as macro headwinds persist.

Market Plunge Uncovers Stock Opportunities

Indian equity markets fell sharply on March 27, 2026, with the Nifty 50 and Sensex shedding over 2% of their value. This downturn was driven by rising geopolitical tensions in the Middle East, leading to a surge in crude oil prices and a record low for the Indian Rupee at 94.82 against the US dollar. Foreign investors continued selling, worsening the market drop. All sectoral indices closed lower, with banking and financial stocks hit hardest by the sell-off. BSE-listed firms lost about ₹9 lakh crore in market value.

Despite this widespread market weakness, certain individual stocks are showing individual strength against the general market downturn. These selections often show technical breakouts or steady upward moves that go against the market trend.

Individual Stocks Show Technical Strength

Several companies are showing strong technical patterns and momentum despite the market slump. Granules India is showing a clear uptrend, with higher highs and lows on daily and weekly charts. It's trading above key moving averages with increasing volume. Federal Bank found support around ₹255-₹252. Recent price action formed a bullish candle, indicating buying interest at lower levels, backed by a positive daily RSI. Emcure Pharmaceuticals clearly broke above ₹1,590 resistance on high volume, showing strong investor interest. It's trading above key moving averages with good RSI readings.

Larsen & Toubro recovered from the ₹3,300 support zone. It's now above key Fibonacci levels, and its 14-day RSI signals a bullish reversal, showing improving momentum. Mankind Pharma is nearing a historical support level. A bullish weekly candlestick and a positive 14-week RSI suggest a potential early reversal and buying opportunity.

Delhivery shows an inverse head and shoulders pattern breakout and a breach of a falling trendline, with rising volumes and an RSI breakout. Trading above upward-sloping EMAs suggests strong bullish momentum, with old resistance now acting as support. Aditya Infotech broke out of a box pattern on significant volume. Its pattern of higher highs and lows, plus trading above rising EMAs, confirms a strong uptrend. The RSI breakout also supports this positive technical outlook.

Analyst Ratings Stay Positive

Even amidst market volatility, analysts remain largely optimistic on these selectively strong stocks. Federal Bank has a 'Buy' consensus from 32 analysts. Their average 12-month price target is ₹294.78, suggesting over 9% upside. Emcure Pharmaceuticals holds a 'Strong Buy' rating from 6 analysts, with an average 12-month price target of ₹1,794.83, offering significant potential upside. Larsen & Toubro also has a 'Strong Buy' consensus from multiple analysts, with an average price target around ₹4,680.83, suggesting over 31% upside potential. Delhivery's analyst consensus is overwhelmingly 'Strong Buy,' with 19 of 22 analysts recommending the stock, and an average price target of ₹523.64. Aditya Infotech is rated 'Strong Buy' by all 4 analysts covering it, with an average target of ₹1,954.00.

Valuation and Sector Insights

The selected stocks operate in sectors showing different levels of resilience. While banking stocks like Federal Bank faced broad selling pressure, IT and electronics hardware sectors saw less impact, with the Nifty IT index being the least affected. Larsen & Toubro, a large infrastructure and engineering company, has a market cap over ₹4.9 lakh crore and a P/E around 30, indicating a premium valuation backed by its project execution. Emcure Pharmaceuticals operates in pharma with a P/E of 35-43, while Aditya Infotech trades at a much higher P/E of 80-91, suggesting high investor expectations for growth, possibly linked to its role in electronics and IT hardware.

Key Risks to Consider

Despite the positive technicals and analyst outlook for these specific names, significant risks persist. Ongoing geopolitical instability in the Middle East could further impact oil prices and global supply chains, posing a threat to India's economy as a net oil importer. The falling rupee adds to macroeconomic worries, raising import costs and potentially squeezing company profits. For individual companies like Aditya Infotech, its very high P/E of 80-90 means the stock trades at a premium, making it vulnerable if growth forecasts aren't met or if market sentiment changes suddenly. L&T's P/E of around 30 is more moderate, but its large projects carry execution and timing risks. Federal Bank is exposed to the banking sector, a top loser on March 27th, making it susceptible to broader risks despite its individual strength.

Future Outlook

The broader market is likely to stay volatile, depending on geopolitical events and commodity prices. However, for the identified stocks, positive technicals and strong analyst confidence suggest these stocks could outperform. Analyst targets suggest significant upside, but this will require a stable economic environment and strong management execution.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.